pcr

Evaluation of 18 commercial serological assays for the detection of antibodies against SARS-CoV-2 in paired serum samples

Evaluation of 18 commercial serological assays for the detection of antibodies against SARS-CoV-2 in paired serum samples

A range of serological checks have been developed to detect the presence of antibodies against the extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated the efficiency of 18 commercially accessible SARS-CoV-2 antibody assays. Early (6-Eight days after the begin of signs) and late sera (>14 days) from ICU sufferers (n=10 and n=16, respectively) and healthcare employees (n=5 and n=9, respectively) have been included. Additionally, 22 sera have been included to detect potential cross-reactivity. Test traits have been decided for the 18 assays. In >14 days samples, the Vircell IgG and Wantai Ig ELISAs had superior sensitivity in comparison with the different ELISAs (96%).

Furthermore, the Roche Ig, the Epitope Diagnostics IgM, Wantai IgM, Euroimmun IgG, and IgA all confirmed a specificity of 100%. The POCTs of Boson Biotech and ACRO Biotech confirmed the highest sensitivities: 100% and 96% (83.5-99.8), respectively. The POCT of Orient Gene Biotech, VOMED Diagnostics, and Coris-Bioconcept confirmed highest specificities (100%). For the IgM and IgA assays, the Euroimmun IgA take a look at confirmed the highest sensitivity in early samples: 46.7% (23.5-70.9) to 53.3% (29.1-76.5). In basic, all checks carried out higher in sufferers with extreme signs (ICU sufferers). We conclude that the Wantai Ig and Vircell IgG ELISAs could also be appropriate for diagnostic functions.

The IgM/IgA checks carried out poorer than their IgG/Ig counterparts however could have a task in diagnoses of SARS-CoV-2 in a inhabitants in which the background seroprevalence of IgG excessive, and IgM and/or IgA could distinguish between acute or previous an infection. The o-rings in ball retained overdentures deteriorate with time and wish alternative to revive the retentive high quality. We evaluated retrospectively the mechanical properties of o-rings after Three years in perform in one and two-piece implant-supported overdentures. The o-rings have been retrieved from one-piece (Myriad snap, Equinox-Straumann, 3.Three x 13mm) and two-piece (Neo Biotech, 3.Three x 13mm) implant-supported overdenture sufferers.

A complete of 16 pairs of matrices have been examined for put on, kind of injury and elasticity utilizing Pin on Disc methodology, USB Digital Camera in 30x zoom and Universal Tensile Machine respectively. The statistical evaluation for impartial teams have been performed with the Mann-Whitney U take a look at. Assessment of used O-rings confirmed 84% extra put on in the two-piece system with an abrasive kind of injury whereas 46% put on in the one-piece system with a compressive kind of injury.

Global Regulation of Genetically Modified Crops Amid the Gene Edited Crop Boom – A Review

Products derived from agricultural biotechnology is quick turning into one of the largest agricultural commerce commodities globally, clothes us, feeding our livestock, and fueling our eco-friendly automobiles. This exponential progress happens regardless of asynchronous regulatory schemes round the world, starting from moratoriums and prohibitions on genetically modified (GM) organisms, to rules that deal with each typical and biotech novel plant merchandise underneath the identical regulatory framework. Given the monumental floor space being cultivated, there is no such thing as a longer a query of acceptance or outright want for biotech crop varieties. Recent recognition of the researchers for the growth of a genome modifying method utilizing CRISPR/Cas9 by the Nobel Prize committee is one other step nearer to growing and cultivating new varieties of agricultural crops.

By using exact, environment friendly, but inexpensive genome modifying methods, new genome edited crops are getting into nation regulatory schemes for commercialization. Countries which at the moment dominate in cultivating and exporting GM crops are shortly recognizing differing kinds of gene-edited merchandise by evaluating the merchandise to conventionally bred varieties. This nuanced legislative growth, first carried out in Argentina, and shortly adopted by many, exhibits appreciable shifts in the panorama of agricultural biotechnology merchandise. The evolution of the legislation on gene edited crops demonstrates that the legislation just isn’t static and should alter to the mores of society, knowledgeable by the experiences of 25 years of cultivation and regulation of GM crops.

The crux of this evaluate is a consolidation of the international legislative panorama on GM crops, because it stands, constructing on earlier works by particularly addressing how gene edited crops will match into the current frameworks. This work is the first of its type to synthesize the relevant regulatory paperwork throughout the globe, with a deal with GM crop cultivation, and gives hyperlinks to unique laws on GM and gene edited crops. Next, an in depth dialogue of the state of the artwork, and technical challenges and alternatives related to C-MEMS and C-NEMS units used in biotech functions are offered.

Evaluation of 18 commercial serological assays for the detection of antibodies against SARS-CoV-2 in paired serum samples

Perspectives on C-MEMS and C-NEMS biotech functions

Carbon microelectromechanical system (C-MEMS) and carbon nanoelectromechanical system (C-NEMS) have been recognized as promising applied sciences for a spread of biotech functions, together with electrochemical biosensors, biofuel cells, neural probes, and dielectrophoretic cell trapping. Research groups round the world have devoted increasingly time to this area. After nearly 20 years of efforts on growing C-MEMS and C-NEMS, a evaluate of the related progress and addressing future analysis alternatives and demanding points is in order. This evaluate first introduces C-MEMS and C-NEMS fabrication processes that fall into two classes: photolithography- and non-photolithography- primarily based methods.

Recombinant (E.Coli) Anti-Tetanus Toxoid scFv IgG

RP-343 10 ug
EUR 343.2

Anti-ROR1 (clone R11) scFv-Fc-Sec ADC

ADC-W-434 1mg Ask for price
Description: This ADC product is comprised of an anti-ROR1 scFv-Fc (clone R11) conjugated via a engineered selenocysteine (Sec) residue linker to a drug

Anti-COVID-19 Nucleocapsid Protein scFv Antibody

E38A9964 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Biotinylated FMC63 scFv, Fc,Avitag™ (MALS verified)

CD9-BV4324b 25ug
EUR 1294.7
Description: Biotinylated FMC63 scFv, Fc, Avitag is a chimeric monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain.

E.coli anti-COVID-19 Nucleocapsid Protein scFv Antibody

DL99719A-100ul 100 ul
EUR 299
Description: Nucleoprotein; Nucleocapsid protein; NC; Protein N

E.coli anti-COVID-19 Nucleocapsid Protein scFv Antibody

DL99719A-50ul 50 ul
EUR 210
Description: Nucleoprotein; Nucleocapsid protein; NC; Protein N

Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ)

78600 50 µl
EUR 1150
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. These viruses constitutively express the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge, 4-1BB, and CD3ζ signaling domains. 

Recombinant Anti-CD3 x Anti-CEA Bispecific Antibody (Tandem scFv)

BSFV-072-100ug 100μg
EUR 4272
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-CEA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Breast cancer; Lung cancer; Gastric cancer therapy.

Recombinant Anti-CD3 x Anti-CEA Bispecific Antibody (Tandem scFv)

BSFV-072-50ug 50μg
EUR 2446.8
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-CEA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Breast cancer; Lung cancer; Gastric cancer therapy.

Recombinant Anti-FIXa x Anti-FX Bispecific Antibody (Tandem scFv)

BSFV-162-100ug 100μg
EUR 4552.8
Description: A bispecific antibody that is expressed as an anti-FIXa scFv fused with an anti-FX scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can bind and dimerize two factors. It acts as mimetic FXIII. It is designed for the research of Hemophilia A therapy.

Recombinant Anti-FIXa x Anti-FX Bispecific Antibody (Tandem scFv)

BSFV-162-50ug 50μg
EUR 2587.2
Description: A bispecific antibody that is expressed as an anti-FIXa scFv fused with an anti-FX scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can bind and dimerize two factors. It acts as mimetic FXIII. It is designed for the research of Hemophilia A therapy.

Recombinant Anti-BSA x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-c001-100ug 100μg
EUR 4552.8
Description: A bispecific antibody that is expressed as an anti-BSA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can be used as a negative control to other anti-CD3 BsAbs in the research of tumor therapy.

Recombinant Anti-BSA x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-c001-50ug 50μg
EUR 2587.2
Description: A bispecific antibody that is expressed as an anti-BSA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can be used as a negative control to other anti-CD3 BsAbs in the research of tumor therapy.

Recombinant Anti-BCMA x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-020-100ug 100μg
EUR 4272
Description: A bispecific antibody that is expressed as an anti-BCMA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Multiple myeloma (MM) therapy.

Recombinant Anti-BCMA x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-020-50ug 50μg
EUR 2446.8
Description: A bispecific antibody that is expressed as an anti-BCMA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Multiple myeloma (MM) therapy.

Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-030-100ug 100μg
EUR 4272
Description: A bispecific antibody that is expressed as an anti-CD123 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy.

Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-030-50ug 50μg
EUR 2446.8
Description: A bispecific antibody that is expressed as an anti-CD123 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy.

Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-041-100ug 100μg
EUR 4552.8
Description: A bispecific antibody that is expressed as an anti-CD19 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.

Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-041-50ug 50μg
EUR 2587.2
Description: A bispecific antibody that is expressed as an anti-CD19 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.

Recombinant Anti-CD2 x Anti-EGFR Bispecific Antibody (Tandem scFv)

BSFV-046-100ug 100μg
EUR 4272
Description: A bispecific antibody that is expressed as an anti-CD2 scFv fused with an anti-EGFR scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.

Recombinant Anti-CD2 x Anti-EGFR Bispecific Antibody (Tandem scFv)

BSFV-046-50ug 50μg
EUR 2446.8
Description: A bispecific antibody that is expressed as an anti-CD2 scFv fused with an anti-EGFR scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.

Recombinant Anti-CD33 x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-066-100ug 100μg
EUR 4272
Description: A bispecific antibody that is expressed as an anti-CD33 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy.

Recombinant Anti-CD33 x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-066-50ug 50μg
EUR 2446.8
Description: A bispecific antibody that is expressed as an anti-CD33 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy.

Recombinant Anti-EGFR x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-077-100ug 100μg
EUR 4272
Description: A bispecific antibody that is expressed as an anti-EGFR scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.

Recombinant Anti-EGFR x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-077-50ug 50μg
EUR 2446.8
Description: A bispecific antibody that is expressed as an anti-EGFR scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.

Recombinant Anti-EPCAM x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-079-100ug 100μg
EUR 4272
Description: A bispecific antibody that is expressed as an anti-EPCAM scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy.

Recombinant Anti-EPCAM x Anti-CD3 Bispecific Antibody (Tandem scFv)

BSFV-079-50ug 50μg
EUR 2446.8
Description: A bispecific antibody that is expressed as an anti-EPCAM scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy.

Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (Tandem scFv)

BSFV-102-100ug 100μg
EUR 4272
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-PSMA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy.

Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (Tandem scFv)

BSFV-102-50ug 50μg
EUR 2446.8
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-PSMA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy.

Anti-Amyloid Beta Reference Antibody (CSIRO anti-amyloid Beta scFv)

E24CHA691 100 μg
EUR 225
Description: Available in various conjugation types.

Anti-CD22 CAR Lentivirus (Clone m971 ScFv-CD8-4-1BB-CD3ζ)

78608 50 µl
EUR 1095
Description: The anti-CD22 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD22 (clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (below).

Anti-BCMA CAR Lentivirus (Clone C11D5.3 ScFv-CD8-4-1BB-CD3ζ)

78655 50 µl
EUR 1095
Description: The anti-BCMA CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-BCMA (clone C11D5.3) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). The lentiviruses also transduce a puromycin selection gene.

GC Control

A23 -
EUR 600
Description: SW module for GC control

LC Control

A24 -
EUR 600
Description: SW module for HPLC/CE control (pump, det, etc.)

AS Control

A26 -
EUR 330
Description: SW module for AS control

Rat Control

DEV99RC 2 x 1 ml
EUR 60

Rat neurofascin (Nfasc)-control Control/blocking peptide

AB-23249-CP 100ug
EUR 196.8

Anti-CD20 CAR Lentivirus (Clone Leu-16 ScFv-CD8-4-1BB-CD3ζ)

78606 50 µl
EUR 1095
Description: The anti-CD20 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD20 (clone Leu-16) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains .

Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector)

78601 50 µl
EUR 1150
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, 4-1BB and CD3ζ signaling domains .Note: This product transduces the same construct as the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ) (BPS Bioscience #78600), but differs in key aspects:78601 is constructed with a SIN lentivector while 78600 is not. 78601 does not contain an antibiotic for selection while 78600 contains a puromycin selection so the transduced cells can be selected with puromycin.

pMD18- Control

PVT10563 2 ug
EUR 319.2

pMD19- Control

PVT10564 2 ug
EUR 319.2

Rat IgG-PE conjugate (isotype control) (Isotype control)

20005-PE 25 tests
EUR 242.4

Dengue Control

ant-543 100µg
EUR 165
Description: Mouse Anti-Dengue Control for Lateral Flow Test

Control Slides

24012-1 1box
EUR 78

Canine Control

DEV99CC 2 x 1 ml
EUR 60

Rat IgG-HRP conjugate (isotype control) (Isotype control)

20005-HP 100 ug
EUR 196.8

Rat IgG-FITC conjugate (isotype control) (Isotype control)

20005-F 100 ug
EUR 196.8

Quality Control

abx098966-1vial 1 vial
EUR 360

Rat IgG-Biotin conjugate (isotype control) (Isotype control)

20005-B 100 ug
EUR 196.8

PIPET CONTROLLER CONTROL BOARD

357484 1/pk
EUR 104.4
Description: Falcon Liquid Handling Equipment; Falcon Pipet Controllers and Accessories

Goat IgG (-ve control for flow cytometry) (isotype control)

20011-100 100 test
EUR 123.6

Control siRNA Vector (pGB-control)

9500C-20 each
EUR 405.6

OOSA10387-100T - IgM NEGATIVE CONTROL Negative/Isotype Control

OOSA10387-100T 100Tests
EUR 309

OOSA10342-100UG - IgG1 NEGATIVE CONTROL Negative/Isotype Control

OOSA10342-100UG 0.1mg
EUR 219

OOSA10349-100T - IgG2a NEGATIVE CONTROL Negative/Isotype Control

OOSA10349-100T 100Tests
EUR 299

OOSA10380-100T - IgG2b NEGATIVE CONTROL Negative/Isotype Control

OOSA10380-100T 100Tests
EUR 309

OOSA10389-100T - IgG1 NEGATIVE CONTROL Negative/Isotype Control

OOSA10389-100T 100Tests
EUR 309

OOSA10397-100T - IgG2a NEGATIVE CONTROL Negative/Isotype Control

OOSA10397-100T 100Tests
EUR 309

EUROSTAR 200 control Overhead Stirrer with wireless control unit

STI2876 EACH
EUR 5433.6

EUROSTAR 100 control Overhead Stirrer with wireless control unit

STI2878 EACH
EUR 3648

Rat Control IgG

AC034 100 ul
EUR 159.6

β-Gal Control

LV007 4 x 500 ul
EUR 195

NF-κB Control

T37559-10mg 10mg Ask for price
Description: NF-κB Control

NF-κB Control

T37559-1g 1g Ask for price
Description: NF-κB Control

NF-κB Control

T37559-1mg 1mg Ask for price
Description: NF-κB Control

NF-κB Control

T37559-50mg 50mg Ask for price
Description: NF-κB Control

NF-κB Control

T37559-5mg 5mg Ask for price
Description: NF-κB Control

EDG-1 Control

BC-009 100 uL
EUR 350

EDG-2 Control

BC-011 100 uL
EUR 350

EDG-4 Control

BC-012 100 uL
EUR 350

EDG-6 Control

BC-014 100 uL
EUR 350

EDG-7 Control

BC-016 100 uL
EUR 350

EUROSTAR 60 control Overhead Stirrer with wireless control unit

STI2886 EACH
EUR 2894.4

Goat IgG control

31R-AG001 1 mg
EUR 152.4
Description: Goat Immunoglobulins Goat IgG control

Goat IgG Control

GT15900 1 mg
EUR 199.2

MG-BSA Control

STA-306 100 µg
EUR 386.4
Description:
  • Methylglyoxal-BSA (MG-BSA) may be used as a positive control. 100 µg at 1 mg/mL in PBS.
  • Provided at 1 mg/mL

Mouse IgG Control

10R-I169A 250 ug
EUR 152.4
Description: Mouse Immunoglobulins Mouse IgG Control

Mouse Control IgG

AC011 100 ul
EUR 159.6

Mouse IgM Control

ICIGMF-100 100 µg
EUR 239.4

Mouse IgM Control

ICIGMPU-100 100 µg
EUR 239.4

CEL-BSA Control

STA-302 100 µg
EUR 386.4
Description:
  • N-epsilon-(carboxyethyl) lysine (CEL) modified BSA may be used as a positive control. 100 µg at 1 mg/mL in PBS.
  • Provided at 1 mg/mL in 1X PBS

CML-BSA Control

STA-314 100 µg
EUR 386.4
Description:
  • CML-BSA may be used as a positive control. 100 µg.
  • Provided at 1 mg/mL in 1X PBS

MDA-BSA Control

STA-333 100 µg
EUR 386.4
Description:
  • MDA-BSA (Malondialdehyde-BSA) may be used as a positive control. 100 µg.
  • Provided at 1 mg/mL in 1X PBS

HNE-BSA Control

STA-335 100 µg
EUR 386.4
Description:
  • HNE-BSA (4-Hydroxynonenal-BSA) may be used as a positive control. 100 µg.
  • Provided at 1 mg/mL in 1X PBS

human IgM control

E4A11C04 50ug
EUR 255
Description: Available in various conjugation types.

human IgE control

E4A11C05 50ug
EUR 255
Description: Available in various conjugation types.

Vacuum Controller w Control Unit

PUM3016 EACH
EUR 2559.6

OOSA10361-1ML - Rat IgG2a NEGATIVE CONTROL Negative/Isotype Control

OOSA10361-1ML 1ml
EUR 169

Rabbit Control IgG

AC005 100 ul
EUR 159.6

Rabbit IgG Control

31R-AR001 500 ug
EUR 159.6
Description: Purified Normal Rabbit IgG

Human IgG1 Control

HY-P9900 5mg
EUR 776.4

Mouse IgG1 Control

ICIGG1A-50 50 µg
EUR 387.6

Mouse IgG1 Control

ICIGG1AC750-50 50 µg
EUR 855.6

Mouse IgG1 Control

ICIGG1CFB-100 100 µg
EUR 387.6

Mouse IgG1 Control

ICIGG1F-100 100 µg
EUR 239.4

Mouse IgG1 Control

ICIGG1PE-50 50 µg
EUR 387.6

Mouse IgG1 Control

ICIGG1PP-100 100 µg
EUR 387.6

Mouse IgG1 Control

ICIGG1PP5.5-100 100 µg
EUR 387.6

Mouse IgG1 Control

ICIGG1PU-100 100 µg
EUR 239.4

Mouse IgG3 Control

ICIGG3A-50 100 µg
EUR 777.6

Mouse IgG3 Control

ICIGG3CFB-100 100 µg
EUR 465.6

Mouse IgG3 Control

ICIGG3F-100 100 µg
EUR 387.6

Mouse IgG3 Control

ICIGG3PE-50 50 µg
EUR 621.6

Mouse IgG3 Control

ICIGG3PU-100 100 µg
EUR 387.6

VACUUM CONTROL KIT

ZAFSVCKIT EACH
EUR 381.24

human IgG1 control

E4A11C03 50ug
EUR 255
Description: Available in various conjugation types.

PAS Control Slides

HCS1016-25 25 Slides
EUR 137.81

CD3 Control Slides

ICS2005-25 25 Slides
EUR 137.81

CD5 Control Slides

ICS2006-25 25 Slides
EUR 137.81

CD8 Control Slides

ICS2007-25 25 Slides
EUR 137.81

CEA Control Slides

ICS2012-25 25 Slides
EUR 137.81

EMA Control Slides

ICS2018-25 25 Slides
EUR 137.81

These units are mentioned in the related sub-sections of biosensors, biofuel cells, intracorporeal neural probe, dielectrophoresis cell trapping, and cell tradition. The evaluate concludes with an exposition of future views in C-MEMS and C-NEMS. The o-rings in one-piece system confirmed enhance in elongation and most displacement to 2% and seven% respectively, whereas two-piece system confirmed lower in elongation and most displacement by 13% and 6% respectively. In one-piece system, the loss of retention was extra with gradual put on fee and in two-piece system, the put on resistance of O-rings decreased as a consequence of elevated stiffness. Further research to guage the adjustments in O-ring with elevated pattern dimension and at interval 1 yr will pave approach for perception into the progressive adjustments in the mechanical properties of an O-ring.